<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="600">
	<fontspec id="0" size="10" family="MinionPro" color="#231f20"/>
	<fontspec id="1" size="8" family="HKIIGD+MinionPro" color="#100e0c"/>
	<fontspec id="2" size="8" family="HKIIGC+MinionMath" color="#100e0c"/>
	<fontspec id="3" size="9" family="MinionPro" color="#231f20"/>
	<fontspec id="4" size="9" family="MinionMath" color="#231f20"/>
	<fontspec id="5" size="9" family="MinionPro-It" color="#231f20"/>
	<fontspec id="6" size="10" family="MinionMath" color="#231f20"/>
	<fontspec id="7" size="10" family="MinionPro" color="#000000"/>
	<fontspec id="8" size="7" family="MinionMath-Capt" color="#231f20"/>
<text top="44" left="51" width="117" height="10" font="0">Analytical Cellular Pathology</text>
<text top="44" left="544" width="5" height="10" font="0">7</text>
<text top="86" left="69" width="25" height="8" font="1">Endo H</text>
<text top="151" left="59" width="12" height="8" font="1">130</text>
<text top="164" left="59" width="12" height="8" font="1">100</text>
<text top="93" left="53" width="19" height="8" font="1">(kDa)</text>
<text top="100" left="59" width="12" height="8" font="1">170</text>
<text top="111" left="59" width="12" height="8" font="1">130</text>
<text top="127" left="59" width="12" height="8" font="1">100</text>
<text top="109" left="257" width="23" height="8" font="1">Mature</text>
<text top="122" left="257" width="31" height="8" font="1">Precursor</text>
<text top="196" left="257" width="28" height="8" font="1">GAPDH</text>
<text top="201" left="63" width="8" height="8" font="1">35</text>
<text top="75" left="206" width="14" height="8" font="1">CsA</text>
<text top="73" left="222" width="5" height="10" font="2">+</text>
<text top="75" left="229" width="16" height="8" font="1">Rapa</text>
<text top="85" left="100" width="5" height="10" font="2">âˆ’</text>
<text top="85" left="119" width="5" height="10" font="2">+</text>
<text top="85" left="156" width="5" height="10" font="2">+</text>
<text top="85" left="176" width="5" height="10" font="2">âˆ’</text>
<text top="85" left="193" width="5" height="10" font="2">+</text>
<text top="85" left="214" width="5" height="10" font="2">âˆ’</text>
<text top="85" left="233" width="5" height="10" font="2">+</text>
<text top="85" left="137" width="5" height="10" font="2">âˆ’</text>
<text top="75" left="178" width="16" height="8" font="1">Rapa</text>
<text top="75" left="142" width="14" height="8" font="1">CsA</text>
<text top="75" left="107" width="5" height="8" font="1">C</text>
<text top="95" left="260" width="9" height="10" font="2">ğ›½1</text>
<text top="160" left="257" width="9" height="10" font="2">ğ›½3</text>
<text top="219" left="51" width="240" height="9" font="3">Figure 3: Rapamycin (Rapa) and the combination of cyclosporin A</text>
<text top="229" left="51" width="91" height="9" font="3">(CsA) and Rapa changes</text>
<text top="227" left="144" width="5" height="12" font="4">ğ›½</text>
<text top="229" left="150" width="20" height="9" font="3">1 and</text>
<text top="227" left="172" width="5" height="12" font="4">ğ›½</text>
<text top="229" left="177" width="113" height="9" font="3">3 integrin expression on MLR-</text>
<text top="240" left="51" width="240" height="9" font="3">activated cells. Peripheral blood mononuclear cells were cultured</text>
<text top="250" left="51" width="240" height="9" font="3">for 6 days in the presence of CsA (200 ng per 1 mL medium),</text>
<text top="261" left="51" width="240" height="9" font="3">Rapa (20 ng per 1 mL medium), and the combination of CsA</text>
<text top="271" left="51" width="240" height="9" font="3">(150 ng per 1 mL medium) and Rapa (12 ng per 1 mL medium)</text>
<text top="282" left="51" width="240" height="9" font="3">in a two-way mixed leukocyte reaction (MLR) and then lysed in</text>
<text top="292" left="51" width="120" height="9" font="3">RIPA buffer. Protein extracts (15</text>
<text top="290" left="172" width="5" height="12" font="4">ğœ‡</text>
<text top="292" left="177" width="105" height="9" font="3">g) were digested with endo-</text>
<text top="290" left="282" width="5" height="12" font="4">ğ›½</text>
<text top="292" left="287" width="3" height="9" font="3">-</text>
<text top="303" left="51" width="160" height="9" font="3">N-acetylglucosaminidase H (Endo H) from</text>
<text top="303" left="213" width="75" height="9" font="5"><i>Streptomyces plicatus</i></text>
<text top="303" left="289" width="2" height="9" font="3">,</text>
<text top="313" left="51" width="240" height="9" font="3">SDS-PAGE-separated on 10% gel under reducing conditions, elec-</text>
<text top="324" left="51" width="240" height="9" font="3">troblotted onto a PVDF membrane, and probed with specific pri-</text>
<text top="334" left="51" width="149" height="9" font="3">mary antibodies: mouse monoclonal anti-</text>
<text top="332" left="199" width="5" height="12" font="4">ğ›½</text>
<text top="334" left="205" width="86" height="9" font="3">1 (Chemicon, MAB2251,</text>
<text top="344" left="51" width="149" height="9" font="3">clone B3B11) and rabbit polyclonal anti-</text>
<text top="342" left="200" width="5" height="12" font="4">ğ›½</text>
<text top="344" left="205" width="86" height="9" font="3">3 (Chemicon, AB1932).</text>
<text top="355" left="51" width="240" height="9" font="3">Antibody-bound integrins were visualized by chemiluminescence.</text>
<text top="365" left="51" width="201" height="9" font="3">GAPDH was the endogenous control. C: untreated cells.</text>
<text top="405" left="55" width="19" height="8" font="1">(kDa)</text>
<text top="415" left="58" width="12" height="8" font="1">170</text>
<text top="422" left="58" width="12" height="8" font="1">130</text>
<text top="431" left="58" width="12" height="8" font="1">100</text>
<text top="419" left="254" width="23" height="8" font="1">Mature</text>
<text top="426" left="254" width="31" height="8" font="1">Precursor</text>
<text top="458" left="62" width="8" height="8" font="1">35</text>
<text top="452" left="255" width="28" height="8" font="1">GAPDH</text>
<text top="395" left="197" width="14" height="8" font="1">CsA</text>
<text top="393" left="213" width="5" height="10" font="2">+</text>
<text top="395" left="220" width="16" height="8" font="1">Rapa</text>
<text top="395" left="169" width="16" height="8" font="1">Rapa</text>
<text top="395" left="133" width="14" height="8" font="1">CsA</text>
<text top="395" left="99" width="5" height="8" font="1">C</text>
<text top="406" left="88" width="4" height="8" font="1">L</text>
<text top="406" left="102" width="4" height="8" font="1">S</text>
<text top="406" left="115" width="5" height="8" font="1">P</text>
<text top="406" left="128" width="4" height="8" font="1">L</text>
<text top="406" left="142" width="4" height="8" font="1">S</text>
<text top="406" left="154" width="15" height="8" font="1">P L</text>
<text top="406" left="179" width="4" height="8" font="1">S</text>
<text top="406" left="191" width="5" height="8" font="1">P</text>
<text top="406" left="204" width="4" height="8" font="1">L</text>
<text top="406" left="218" width="4" height="8" font="1">S</text>
<text top="406" left="231" width="5" height="8" font="1">P</text>
<text top="407" left="262" width="9" height="10" font="2">ğ›½1</text>
<text top="475" left="51" width="240" height="9" font="3">Figure 4: High-mannose/hybrid-type glycans are present mainly</text>
<text top="486" left="51" width="51" height="9" font="3">on premature</text>
<text top="484" left="105" width="5" height="12" font="4">ğ›½</text>
<text top="486" left="110" width="180" height="9" font="3">1 integrin subunit. Cell lysate (L), glycoproteins</text>
<text top="496" left="51" width="240" height="9" font="3">precipitated with GNA-agarose (P), and supernatant collected after</text>
<text top="507" left="51" width="240" height="9" font="3">precipitation (S), containing proteins not recognized by GNA,</text>
<text top="517" left="51" width="240" height="9" font="3">were resolved on 10% SDS-PAGE gel under reducing conditions,</text>
<text top="528" left="51" width="200" height="9" font="3">electrotransferred to a PVDF membrane and destined for</text>
<text top="526" left="252" width="5" height="12" font="4">ğ›½</text>
<text top="528" left="258" width="33" height="9" font="3">1 integrin</text>
<text top="538" left="51" width="240" height="9" font="3">subunit immunodetection. GAPDH was the endogenous control. C:</text>
<text top="549" left="51" width="207" height="9" font="3">untreated cells, CsA: cyclosporin A, and Rapa: rapamycin.</text>
<text top="586" left="51" width="240" height="10" font="0">anti-LFA-1 protects against MHC-incompatible graft rejec-</text>
<text top="597" left="51" width="240" height="10" font="0">tion of fetal small bowel grafts transplanted into mice, making</text>
<text top="608" left="51" width="240" height="10" font="0">this integrin a potential target for immunosuppression in</text>
<text top="620" left="51" width="240" height="10" font="0">intestinal transplantation. In turn, the effect of the novel</text>
<text top="631" left="51" width="240" height="10" font="0">immunosuppressive drug mycophenolate mofetil (MMF) on</text>
<text top="642" left="51" width="240" height="10" font="0">tumor cells was dose- and cell line-dependent. In kidney</text>
<text top="654" left="51" width="240" height="10" font="0">carcinoma Caki I cells and pancreatic carcinoma DanG cells</text>
<text top="665" left="51" width="62" height="10" font="0">treated with 0.1</text>
<text top="663" left="115" width="6" height="13" font="6">ğœ‡</text>
<text top="665" left="121" width="33" height="10" font="0">M and 1</text>
<text top="663" left="156" width="6" height="13" font="6">ğœ‡</text>
<text top="665" left="162" width="129" height="10" font="0">M MMF, the expression of inte-</text>
<text top="676" left="51" width="46" height="10" font="0">grins of the</text>
<text top="674" left="99" width="6" height="13" font="6">ğ›½</text>
<text top="676" left="105" width="51" height="10" font="0">1 subfamily (</text>
<text top="674" left="156" width="6" height="13" font="6">ğ›¼</text>
<text top="676" left="161" width="3" height="10" font="0">1</text>
<text top="674" left="165" width="6" height="13" font="6">ğ›½</text>
<text top="676" left="170" width="6" height="10" font="0">1,</text>
<text top="674" left="179" width="6" height="13" font="6">ğ›¼</text>
<text top="676" left="184" width="5" height="10" font="0">2</text>
<text top="674" left="189" width="6" height="13" font="6">ğ›½</text>
<text top="676" left="195" width="6" height="10" font="0">1,</text>
<text top="674" left="203" width="6" height="13" font="6">ğ›¼</text>
<text top="676" left="208" width="5" height="10" font="0">3</text>
<text top="674" left="213" width="6" height="13" font="6">ğ›½</text>
<text top="676" left="219" width="6" height="10" font="0">1,</text>
<text top="674" left="227" width="6" height="13" font="6">ğ›¼</text>
<text top="676" left="233" width="5" height="10" font="0">4</text>
<text top="674" left="238" width="6" height="13" font="6">ğ›½</text>
<text top="676" left="243" width="6" height="10" font="0">1,</text>
<text top="674" left="252" width="6" height="13" font="6">ğ›¼</text>
<text top="676" left="257" width="5" height="10" font="0">5</text>
<text top="674" left="262" width="6" height="13" font="6">ğ›½</text>
<text top="676" left="268" width="23" height="10" font="0">1, and</text>
<text top="686" left="51" width="6" height="13" font="6">ğ›¼</text>
<text top="688" left="56" width="5" height="10" font="0">6</text>
<text top="686" left="61" width="6" height="13" font="6">ğ›½</text>
<text top="688" left="67" width="224" height="10" font="0">1) was downregulated; in colonic adenocarcinoma HT-</text>
<text top="699" left="51" width="11" height="10" font="0">29,</text>
<text top="697" left="64" width="6" height="13" font="6">ğ›¼</text>
<text top="699" left="69" width="5" height="10" font="0">3</text>
<text top="697" left="74" width="6" height="13" font="6">ğ›½</text>
<text top="699" left="80" width="22" height="10" font="0">1, and</text>
<text top="697" left="104" width="6" height="13" font="6">ğ›¼</text>
<text top="699" left="109" width="5" height="10" font="0">6</text>
<text top="697" left="114" width="6" height="13" font="6">ğ›½</text>
<text top="699" left="120" width="171" height="10" font="0">1 integrins were upregulated in the presence</text>
<text top="711" left="51" width="13" height="10" font="0">of 1</text>
<text top="708" left="66" width="6" height="13" font="6">ğœ‡</text>
<text top="711" left="71" width="219" height="10" font="0">M MMF; and in prostate carcinoma DU-145 most of the</text>
<text top="722" left="51" width="79" height="10" font="0">analyzed integrins (</text>
<text top="720" left="129" width="6" height="13" font="6">ğ›¼</text>
<text top="722" left="135" width="3" height="10" font="0">1</text>
<text top="720" left="138" width="6" height="13" font="6">ğ›½</text>
<text top="722" left="144" width="6" height="10" font="0">1,</text>
<text top="720" left="152" width="6" height="13" font="6">ğ›¼</text>
<text top="722" left="158" width="5" height="10" font="0">2</text>
<text top="720" left="162" width="6" height="13" font="6">ğ›½</text>
<text top="722" left="168" width="6" height="10" font="0">1,</text>
<text top="720" left="176" width="6" height="13" font="6">ğ›¼</text>
<text top="722" left="182" width="5" height="10" font="0">3</text>
<text top="720" left="186" width="6" height="13" font="6">ğ›½</text>
<text top="722" left="192" width="23" height="10" font="0">1, and</text>
<text top="720" left="218" width="6" height="13" font="6">ğ›¼</text>
<text top="722" left="224" width="5" height="10" font="0">5</text>
<text top="720" left="228" width="6" height="13" font="6">ğ›½</text>
<text top="722" left="234" width="57" height="10" font="0">1) were upreg-</text>
<text top="733" left="51" width="128" height="10" font="0">ulated under both MMF doses [</text>
<text top="733" left="179" width="8" height="10" font="7">41</text>
<text top="733" left="187" width="103" height="10" font="0">]. Dexamethasone (DEX),</text>
<text top="74" left="309" width="240" height="10" font="0">a glucocorticoid used commonly for topical ocular applica-</text>
<text top="85" left="309" width="69" height="10" font="0">tion, upregulated</text>
<text top="83" left="380" width="6" height="13" font="6">ğ›¼</text>
<text top="85" left="386" width="5" height="10" font="0">v</text>
<text top="83" left="390" width="6" height="13" font="6">ğ›½</text>
<text top="85" left="396" width="153" height="10" font="0">3 integrin expression in the N27TM-2</text>
<text top="97" left="309" width="240" height="10" font="0">cell line derived from human ocular trabecular meshwork,</text>
<text top="108" left="309" width="240" height="10" font="0">due to an increase of both the half-life and transcription</text>
<text top="119" left="309" width="8" height="10" font="0">of</text>
<text top="117" left="320" width="6" height="13" font="6">ğ›½</text>
<text top="119" left="326" width="80" height="10" font="0">3 integrin mRNA [</text>
<text top="119" left="406" width="10" height="10" font="7">42</text>
<text top="119" left="415" width="133" height="10" font="0">]. CsA also upregulated integrin</text>
<text top="128" left="309" width="6" height="13" font="6">ğ›½</text>
<text top="131" left="314" width="234" height="10" font="0">3 expression but in a dose-dependent manner, resulting in</text>
<text top="142" left="309" width="240" height="10" font="0">enhanced murine embryonic adhesion and invasion, which</text>
<text top="153" left="309" width="132" height="10" font="0">promoted embryo implantation [</text>
<text top="153" left="441" width="9" height="10" font="7">43</text>
<text top="153" left="450" width="98" height="10" font="0">]. Our work also showed</text>
<text top="165" left="309" width="55" height="10" font="0">an increase of</text>
<text top="162" left="367" width="6" height="13" font="6">ğ›½</text>
<text top="165" left="372" width="21" height="10" font="0">1 and</text>
<text top="162" left="396" width="6" height="13" font="6">ğ›½</text>
<text top="165" left="402" width="147" height="10" font="0">3 integrin expression in the presence</text>
<text top="176" left="309" width="240" height="10" font="0">of a therapeutic dose of Rapa and under CsA and Rapa</text>
<text top="187" left="309" width="76" height="10" font="0">combined (Figures</text>
<text top="187" left="387" width="5" height="10" font="7">3</text>
<text top="187" left="394" width="15" height="10" font="0">and</text>
<text top="187" left="412" width="5" height="10" font="7">4</text>
<text top="187" left="417" width="132" height="10" font="0">). An earlier study demonstrated</text>
<text top="199" left="309" width="54" height="10" font="0">that integrins</text>
<text top="197" left="365" width="6" height="13" font="6">ğ›½</text>
<text top="199" left="371" width="21" height="10" font="0">1 and</text>
<text top="197" left="395" width="6" height="13" font="6">ğ›½</text>
<text top="199" left="401" width="143" height="10" font="0">3 mediate adhesion of murine CD8</text>
<text top="195" left="544" width="4" height="9" font="8">+</text>
<text top="210" left="309" width="240" height="10" font="0">cytotoxic T lymphocytes (CTL) to fibronectin (FN), which</text>
<text top="222" left="309" width="240" height="10" font="0">increased signal triggering by an association of proline-rich</text>
<text top="233" left="309" width="240" height="10" font="0">tyrosine kinase-2 (Pyk2) with paxillin and the Src kinases,</text>
<text top="244" left="309" width="225" height="10" font="0">resulting in MHC I-peptide-driven CTL degranulation [</text>
<text top="244" left="533" width="10" height="10" font="7">48</text>
<text top="244" left="543" width="6" height="10" font="0">].</text>
<text top="253" left="309" width="6" height="13" font="6">ğ›½</text>
<text top="256" left="314" width="20" height="10" font="0">1 and</text>
<text top="253" left="336" width="6" height="13" font="6">ğ›½</text>
<text top="256" left="342" width="207" height="10" font="0">3 integrins participate in adhesion of activated T cells</text>
<text top="267" left="309" width="240" height="10" font="0">to ECM proteins upon TCR triggering or, spontaneously, in</text>
<text top="278" left="309" width="240" height="10" font="0">secondary lymphoid organs or inflamed tissues, where they</text>
<text top="290" left="309" width="164" height="10" font="0">become highly exposed to ECM proteins [</text>
<text top="290" left="473" width="10" height="10" font="7">48</text>
<text top="290" left="483" width="2" height="10" font="0">,</text>
<text top="290" left="487" width="10" height="10" font="7">49</text>
<text top="290" left="496" width="52" height="10" font="0">]. In this con-</text>
<text top="301" left="309" width="165" height="10" font="0">text it is difficult to explain the increase of</text>
<text top="299" left="476" width="6" height="13" font="6">ğ›½</text>
<text top="301" left="482" width="21" height="10" font="0">1 and</text>
<text top="299" left="505" width="6" height="13" font="6">ğ›½</text>
<text top="301" left="510" width="38" height="10" font="0">3 integrin</text>
<text top="312" left="309" width="240" height="10" font="0">expression we observed upon immunosuppressive drug treat-</text>
<text top="324" left="309" width="240" height="10" font="0">ment, but we note that the upregulation of integrin expression</text>
<text top="335" left="309" width="240" height="10" font="0">was accompanied by an increase of high-mannose/hybrid-</text>
<text top="347" left="309" width="97" height="10" font="0">type oligosaccharides on</text>
<text top="344" left="407" width="6" height="13" font="6">ğ›½</text>
<text top="347" left="413" width="20" height="10" font="0">1 and</text>
<text top="344" left="435" width="6" height="13" font="6">ğ›½</text>
<text top="347" left="441" width="108" height="10" font="0">3 integrins, as shown by the</text>
<text top="358" left="309" width="80" height="10" font="0">reaction with GNA (</text>
<text top="358" left="389" width="44" height="10" font="7">Figure 2(a)</text>
<text top="358" left="433" width="116" height="10" font="0">). The total surface expression</text>
<text top="369" left="309" width="240" height="10" font="0">of the high-mannose/hybrid-type N-glycans was also influ-</text>
<text top="381" left="309" width="240" height="10" font="0">enced by the immunosuppressive drugs we used; the combi-</text>
<text top="392" left="309" width="240" height="10" font="0">nation of Rapa and CsA markedly increased the amount of</text>
<text top="403" left="309" width="70" height="10" font="0">those structures (</text>
<text top="403" left="378" width="31" height="10" font="7">Figure 1</text>
<text top="403" left="410" width="139" height="10" font="0">). Only a few previous studies have</text>
<text top="415" left="309" width="240" height="10" font="0">addressed the effect of immunosuppressive agents on leuko-</text>
<text top="426" left="309" width="122" height="10" font="0">cyte glycosylation. Paul et al. [</text>
<text top="426" left="431" width="10" height="10" font="7">46</text>
<text top="426" left="441" width="108" height="10" font="0">] showed that MMF inhib-</text>
<text top="438" left="309" width="240" height="10" font="0">ited IL-1-induced expression of GNA-recognized oligosac-</text>
<text top="449" left="309" width="240" height="10" font="0">charides with terminal mannose (Man) on rat endothelial</text>
<text top="460" left="309" width="240" height="10" font="0">cells. The ability of MMF to downregulate glycosylation</text>
<text top="472" left="309" width="240" height="10" font="0">results from MMF inhibition of inosine-monophosphate</text>
<text top="483" left="309" width="240" height="10" font="0">dehydrogenase, the enzyme that catalyses biosynthesis of</text>
<text top="494" left="309" width="240" height="10" font="0">(deoxy) guanosine nucleotides necessary for transfer of Man</text>
<text top="506" left="309" width="118" height="10" font="0">and fucose to glycoproteins [</text>
<text top="506" left="427" width="10" height="10" font="7">46</text>
<text top="506" left="437" width="2" height="10" font="0">,</text>
<text top="506" left="442" width="10" height="10" font="7">50</text>
<text top="506" left="452" width="97" height="10" font="0">]. MMF-induced reduc-</text>
<text top="517" left="309" width="240" height="10" font="0">tion of the expression and glycosylation of some adhesion</text>
<text top="528" left="309" width="240" height="10" font="0">molecules decreases the recruitment of lymphocytes and</text>
<text top="540" left="309" width="225" height="10" font="0">monocytes to sites of inflammation and graft rejection [</text>
<text top="540" left="533" width="10" height="10" font="7">50</text>
<text top="540" left="543" width="6" height="10" font="0">].</text>
<text top="551" left="309" width="240" height="10" font="0">Itraconazole (Ita), one of the mTOR inhibitors, reduced poly-</text>
<text top="563" left="309" width="240" height="10" font="0">N-acetyllactosamine and tetra-antennary complex-type N-</text>
<text top="574" left="309" width="240" height="10" font="0">glycans in human umbilical vein endothelial cells (HUVEC)</text>
<text top="585" left="309" width="240" height="10" font="0">and caused an increase of Man5GlcNAc2 oligomannose</text>
<text top="597" left="309" width="240" height="10" font="0">structures on vascular endothelial growth factor receptor 2</text>
<text top="608" left="309" width="240" height="10" font="0">(VEGFR2). Hypoglycosylation of VEGFR2 strongly inhibited</text>
<text top="619" left="309" width="197" height="10" font="0">its autophosphorylation after VEGF stimulation [</text>
<text top="619" left="506" width="8" height="10" font="7">15</text>
<text top="619" left="514" width="35" height="10" font="0">]. Induc-</text>
<text top="631" left="309" width="240" height="10" font="0">tion of hypoglycosylation on VEGFR2 in HUVEC cells by</text>
<text top="642" left="309" width="240" height="10" font="0">Ita was similar to the effects of this drug in macrophages</text>
<text top="654" left="309" width="240" height="10" font="0">RAW 264.7. Glycosylphosphatidylinositol-anchored glyco-</text>
<text top="665" left="309" width="240" height="10" font="0">protein CD14 in RAW 264.7 became Endo H-sensitive in</text>
<text top="676" left="309" width="240" height="10" font="0">the presence of Ita. CD14 with altered glycosylation was</text>
<text top="688" left="309" width="240" height="10" font="0">delivered to the cell surface, as determined by binding of</text>
<text top="699" left="309" width="105" height="10" font="0">concanavalin A (Con-A) [</text>
<text top="699" left="414" width="8" height="10" font="7">51</text>
<text top="699" left="422" width="127" height="10" font="0">]. Alteration of glycan synthesis</text>
<text top="710" left="309" width="240" height="10" font="0">by immunosuppressive drugs has also been observed in can-</text>
<text top="722" left="309" width="240" height="10" font="0">cer cells. Treatment of MDA-MB231 breast cancer cells with</text>
<text top="733" left="309" width="194" height="10" font="0">Rapa upregulated the sialylation of N-glycans on</text>
<text top="731" left="505" width="6" height="13" font="6">ğ›½</text>
<text top="733" left="511" width="38" height="10" font="0">1 integrin</text>
</page>
</pdf2xml>
